Dr. Chai-Ann Ng is improving cardiac genetic research with pioneering work in precision medicine for cardiac channelopathies. He developed the first validated assays for ion channel variants, setting new standards. These assays provide reliable data to reclassify Variants of Uncertain Significance (VUS), enabling accurate diagnoses and clinical decisions. His research tackles key challenges in managing conditions like long QT syndrome, distinguishing pathogenic from benign variants with high precision. His functional data improves diagnostic accuracy, risk stratification, and guides interventions like implantable cardioverter-defibrillators. His work also supports targeted pharmacotherapy based on variant-specific defects. Collaborating globally, Dr. Ng has reclassified VUS for hundreds of patients, greatly improving outcomes. His research drives the shift to precision medicine, offering families clear answers, enabling cascade testing, and reducing sudden cardiac death risk. His contributions exemplify innovation with real-world impact, reshaping genetic cardiac disorder management.